ASH 2015 – Multiple Myeloma

Researchers presented data relating to the management of infusion-related reactions (IRRs) associated with single-agent daratumumab treatment in patients with relapsed or refractory multiple myeloma (RRMM) enrolled in the open-label, multicenter, phase 2 Sirius study. Read More ›

Investigators propose moving to a phase 2 evaluation after using a new treatment regimen that was well-tolerated in patients with progressive disease consisting of panobinostat at 20 mg 3 times a week every other week to ixazomib at target 4 mg weekly, 3 weeks on, 1 week off, with dexamethasone 20 mg on the day of and after ixazomib. Read More ›

Read More ›

Researchers reported results of an online survey that examined the preferences of patients with multiple myeloma (MM) on route of administration and individual treatment-related adverse events. Read More ›

Read More ›

R. Donald Harvey conveys his management challenges with patients taking these therapies. Read More ›

Researchers examined subset of elderly newly diagnosed myeloma patients from the GEM2010 trial and split the patients into 2 arms determined by their cytogenetic abnormalities (high risk and standard risk). Patients with 1q gains were shown to have similar outcomes to those without q1 gains when treated with bortezomib plus melphalan and prednisone, followed by lenalidomide and dexamethasone. Read More ›

Researchers demonstrated that any reduction of dose intensity from 1.3 mg/m2 of bortezomib as a first-line treatment for untreated multiple myeloma patients is associated with inferior OS. Furthermore, it was suggested that the cumulative bortezomib dose be ≥20.75 mg for a better OS. Read More ›

The elderly are an important subgroup within multiple myeloma patients, and it is important to continuously monitor MRD to help balance efficacy and toxicity of treatments. Researchers demonstrated that MRD negativity was associated with significant improved survival regardless of age or cytogenetic risk. Read More ›

Filanesib, a kinesin spindle protein inhibitor, has demonstrated promising clinical activity in patients with multiple myeloma refractory to proteasome inhibitors and immunomodulatory drugs. This new combination demonstrated good tolerability and an increased observed response rate compared with carfilzomib alone. Read More ›